Replies to post #1371 on Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

Thanks. Got them . Very interesting. I think they quantify the death/transplant risk reduction and confirm what we already knew. That a reduction in MELD score will significantly reduce death risk. But we still need to confirm that reducing MELD score with Emricasan will have the same effect on death/trasnplant risk. That is why the FDA wants clinical endpoints trial for ENCORE LF